Status:
COMPLETED
Usage of Acyclovir for Suppression of HIV-1 and HSV-2 Coinfected Persons in Cameroon
Lead Sponsor:
Fred Hutchinson Cancer Center
Collaborating Sponsors:
Institute for the Development of Africa
Conditions:
HIV-1 and HSV-2 Coinfection
HIV Infections
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The study proposed that both clinical and subclinical HSV reactivation is associated with increased HIV shedding from mucosal surfaces, which may increase the infectiousness of HIV-1/HSV-2 coinfected ...
Detailed Description
The main objective is to assess the reduction in genital HIV-1 shedding associated with daily acyclovir for suppression of HSV-2 reactivation. All patients will be treated with the usual antibiotic t...
Eligibility Criteria
Inclusion
- 18 years old and above
- Documented HIV-seropositive
- HSV-2 seropositive as determined by Focus EIA
- Not intending to move out of the area for the duration of study participation
- Willing and able to:
- provide independent written informed consent
- undergo clinical evaluations
- take study drug as directed
- adhere to follow-up schedule
- Bacterial STDs (symptomatic STD syndromes or laboratory-confirmed asymptomatic gonorrhea, chlamydia, syphilis) are treated within two weeks if study enrollment and random assignment.
Exclusion
- Women who meet any of the following criteria are not eligible for this study.
- Known history of adverse reaction to acyclovir
- Planned open label use of acyclovir, valacyclovir, or famciclovir
- Positive pregnancy test
- Active opportunistic infection
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2007
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00209313
Start Date
March 1 2005
End Date
April 1 2007
Last Update
December 16 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Central
Yaoundé, Cameroon